Upadacitinib

Upadacitinib is an oral selective inhibitor of Janus associated kinase 1 (JAK-1) that is used in the therapy of moderate-to-severe rheumatoid arthritis. Upadacitinib has been associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury although it may pose a risk for reactivation of hepatitis B in susceptible patients. It is grouped under the following drug class(es): Immunosuppressants, JAK inhibitors, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories, antirheumatic agents and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Upadacitinib anhydrous and upadacitinibum. Its PubChem CID is 58557659.

CAS No 1310726-60-3
Molecular Formula C17H19F3N6O
Molecular Weight 380.40 g/mol
Synonyms (3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo[7.3.0.02,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

Frequently Asked Questions